Intellia Therapeutics Inc Call To Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Transcript
Good afternoon, and welcome to Intellia Therapeutics investor event to discuss the interim clinical results from the Phase I study of NTLA-2001. This conference is being recorded at the company's request and will be available on the company's website following the end of the call.
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Thank you, operator, and good afternoon, everyone. Welcome to Intellia's presentation of additional interim data from the Phase I clinical trial of NTLA-2001 for the treatment of ATTR amyloidosis.
Earlier this afternoon, we issued a press release detailing the results from our ongoing study. This release and the accompanying slide presentation can be found on the Investors and Media section of Intellia's website at intelliatx.com. As a reminder, this call is being broadcast live, and a replay of the event will be archived on Intellia's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
